Press Release Aug 08 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Prucalopride Tablets in two dosages. Prucalopride is used to treat chronic idiopathic constipation and aids in promoting regular bowel movements. The tablets will be manufactured at Zydus's facility in Ahmedabad, and the product had significant annual sales in the United States. This filing serves to inform investors and the stock exchange about this important regulatory approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 07 2025
- Press Release Jul 29 2025
- Press Release Jul 24 2025
- Press Release 17-07-2025 NewspaperpublicationAGMnotice17072025
- Press Release Jul 16 2025
Later from Zydus Lifesciences
- Press Release Aug 11 2025
- Press Release Aug 12 2025
- Press Release Aug 13 2025
- Press Release 20-08-2025 Newspaperadvertisement20082025
- Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences